Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 7;31(29):105210.
doi: 10.3748/wjg.v31.i29.105210.

Predictive value of core-fucosylated low-molecular-weight kininogen levels in patients with liver fibrosis: A prospective study

Guo-Feng Gao  1 , Jiao Yu  1 , Lin Tong  2 , Dong Jiang  3
Affiliations

Predictive value of core-fucosylated low-molecular-weight kininogen levels in patients with liver fibrosis: A prospective study

Guo-Feng Gao et al. World J Gastroenterol. .

Abstract

Background: Core-fucosylated low-molecular-weight kininogen (LMWK-Fc) levels are significantly elevated in patients with liver fibrosis and cirrhosis.

Aim: To assess the value of LMWK-Fc as a diagnostic biomarker for liver fibrosis.

Methods: Our study included 132 healthy people and 132 patients with liver fibrosis. The LMWK-Fc level was measured based on the principle of chemiluminescence. Fibrosis stage and inflammatory activity were assessed by liver biopsy. Comparative analysis between groups and receiver operating characteristic curve analysis were performed.

Results: LMWK-Fc had an area under the curve of 0.871, which indicates a good level of performance in distinguishing between patients with and without fibrosis. Furthermore, the LMWK-Fc level had a certain correlation with the liver stiffness value, which reached 0.5789.

Conclusion: LMWK-Fc could be used as a non-invasive marker of liver fibrosis. Further studies are needed to evaluate the usefulness of this marker.

Keywords: Cirrhosis; Core-fucosylated low-molecular-weight kininogen; Liver fibrosis; Non-invasive marker; Transient elastography.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Figures

Figure 1
Figure 1
Receiver operating characteristic curve analysis of core-fucosylated low-molecular-weight kininogen and other biomarkers. ROC: Receiver operating characteristic; AUC: Area under the curve; APRI: Aminotransferase-to-platelet ratio index; LMWK: Low-molecular-weight kininogen; GGT: Gamma-glutamyl transferase; ALP: Alkaline phosphatase.
Figure 2
Figure 2
Nomogram for low-molecular-weight kininogen and other biomarkers. LMWK: Low-molecular-weight kininogen; APRI: Aminotransferase-to-platelet ratio index; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transferase.
Figure 3
Figure 3
Receiver operating characteristic curve analysis for the nomogram. AUC: Area under the curve.
Figure 4
Figure 4
Clinical decision curve for the nomogram.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023;20:633–646. - PubMed
    1. Man S, Deng Y, Ma Y, Fu J, Bao H, Yu C, Lv J, Liu H, Wang B, Li L. Prevalence of Liver Steatosis and Fibrosis in the General Population and Various High-Risk Populations: A Nationwide Study With 5.7 Million Adults in China. Gastroenterology. 2023;165:1025–1040. - PubMed
    1. Berumen J, Baglieri J, Kisseleva T, Mekeel K. Liver fibrosis: Pathophysiology and clinical implications. WIREs Mech Dis. 2021;13:e1499. - PMC - PubMed
    1. Zhang CY, Liu S, Yang M. Treatment of liver fibrosis: Past, current, and future. World J Hepatol. 2023;15:755–774. - PMC - PubMed
    1. Liedtke C, Nevzorova YA, Luedde T, Zimmermann H, Kroy D, Strnad P, Berres ML, Bernhagen J, Tacke F, Nattermann J, Spengler U, Sauerbruch T, Wree A, Abdullah Z, Tolba RH, Trebicka J, Lammers T, Trautwein C, Weiskirchen R. Liver Fibrosis-From Mechanisms of Injury to Modulation of Disease. Front Med (Lausanne) 2021;8:814496. - PMC - PubMed